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Summary
Background The comparative performance of existing models for prediction of type 2 diabetes across populations has 
not been investigated. We validated existing non-laboratory-based models and assessed variability in predictive 
performance in European populations.
Methods We selected non-invasive prediction models for incident diabetes developed in populations of European 
ancestry and validated them using data from the EPIC-InterAct case-cohort sample (27 779 individuals from eight 
European countries, of whom 12 403 had incident diabetes). We assessed model discrimination and calibration for 
the ﬁ rst 10 years of follow-up. The models were ﬁ rst adjusted to the country-speciﬁ c diabetes incidence. We did the 
main analyses for each country and for subgroups deﬁ ned by sex, age (<60 years vs ≥60 years), BMI (<25 kg/m² vs 
≥25 kg/m²), and waist circumference (men <102 cm vs ≥102 cm; women <88 cm vs ≥88 cm).
Findings We validated 12 prediction models. Discrimination was acceptable to good: C statistics ranged from 0·76 
(95% CI 0·72–0·80) to 0·81 (0·77–0·84) overall, from 0·73 (0·70–0·76) to 0·79 (0·74–0·83) in men, and from 0·78 
(0·74–0·82) to 0·81 (0·80–0·82) in women. We noted signiﬁ cant heterogeneity in discrimination (pheterogeneity<0·0001) 
in all but one model. Calibration was good for most models, and consistent across countries (pheterogeneity>0·05) except 
for three models. However, two models overestimated risk, DPoRT by 34% (95% CI 29–39%) and Cambridge by 40% 
(28–52%). Discrimination was always better in individuals younger than 60 years or with a low waist circumference 
than in those aged at least 60 years or with a large waist circumference. Patterns were inconsistent for BMI. All 
models overestimated risks for individuals with a BMI of <25 kg/m². Calibration patterns were inconsistent for age 
and waist-circumference subgroups.
Interpretation Existing diabetes prediction models can be used to identify individuals at high risk of type 2 diabetes in 
the general population. However, the performance of each model varies with country, age, sex, and adiposity.
Funding The European Union.
Introduction
The number of individuals with type 2 diabetes is 
high and increasing rapidly: 366 million people 
worldwide were estimated to have type 2 diabetes in 
2011, and prevalence is expected to rise by 51% by 2030.1 
Diabetes is associated with increased morbidity and 
mortality, and accounts for a substantial proportion of 
use of health-care resources worldwide.1 Several studies 
have convincingly shown that early interventions can 
prevent or postpone type 2 diabetes.2,3 The cost of these 
interventions and their constraints for individuals are 
arguments against their provision, particularly for 
people at low risk of diabetes. Therefore, appropriate 
identi ﬁ cation of individuals at high risk is important.
Several risk scores to predict type 2 diabetes have 
been developed.4–7 They vary in many ways, such as the 
time horizon for prediction and number and nature of 
predictors. Some models are based on non-laboratory 
clinical variables (non-invasive risk scores); others 
have also incorporated biological variables (invasive 
risk scores). Non-invasive risk scores have been shown 
to identify a high risk of type 2 diabetes (C statistics 
≥0·8), although invasive risk scores are more 
successful (C statistics ~0·9).8 The use of non-invasive 
risk scores is more likely to be cost eﬀ ective and 
feasible for large-scale screening than is use of invasive 
risk scores. Generally, the use of risk scores has been 
widely incorporated into strategies for diabetes 
prevention.9,10 However, risk scores might not be 
generalisable from one population to another, and the 
validity of existing diabetes risk scores in diﬀ erent 
settings and subgroups on the basis of sex or BMI has 
not been established.10
We aimed to validate and compare existing non-
invasive prediction models for type 2 diabetes in 
European populations. We assessed variability in 
predictive performance between countries and by sex, 
BMI, waist circumference, and age.
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Methods 
Study design and population
We used the EPIC-InterAct case-cohort sample 
(27 779 participants, of whom 12 403 had incident 
diabetes), which was selected from the European 
Investigation into Cancer and Nutrition (EPIC) cohort 
study (455 569 participants; appendix p 4).11 The design 
and methods of the InterAct study have been described 
elsewhere.11 Brieﬂ y, the InterAct study was designed to 
investigate how genes and lifestyle factors interact to 
inﬂ uence risk of type 2 diabetes. The InterAct consortium 
partners ascertained and veriﬁ ed incident cases of type 2 
diabetes in EPIC cohorts between 1991 and 2007, from 
eight of the ten EPIC countries (26 centres).
Participants gave written informed consent for 
participation in the EPIC study. The study was approved 
by the local ethics committees in the participating 
countries and the internal review board of the 
International Agency for Research on Cancer (Lyon, 
France).
Procedures
Self-administered questionnaires provided baseline 
information about lifestyle and medical history in the 
case-cohort sample. Validated instruments were used to 
assess nutritional variables12 and physical activity.13 
Blood pressure and anthropometric measurements 
followed standard approaches (appendix p 5). We 
handled missing data in three ways: proxy variables 
(appendix p 6) or exclusion of the predictor from the 
model; exclusion of countries from speciﬁ c analyses 
(appendix p 11); and imputation of missing values by 
country with R’s AregImpute Function, which takes all 
aspects of uncertainty in the imputations into account 
by using the bootstrap to estimate the process of 
drawing predicted values from a full Bayesian predictive 
distribution.
Existing non-invasive prediction models for incident 
diabetes had been identiﬁ ed through a systematic 
review, as previously described.8 We included in this 
study only models developed in general populations of 
European ancestry. We ﬁ rst validated the original 
models by computing the predicted probability of 
diabetes for each participant in the EPIC-InterAct case-
cohort with baseline values (appendix p 7). We expressed 
models’ performance in terms of discrimination 
(whether the model can distinguish between people 
who do and do not develop diabetes) and calibration (to 
what extent the predicted probabilities agree with the 
reported risk across groups of individuals). We assessed 
discrimination with the C statistic (which is comparable 
to the area under the receiver operator characteristic 
curve) adapted for time-to-event data.14 C statistics vary 
from 0·5 (no discrimination) to 1 (perfect dis-
crimination), with values of 0·7–0·8 deemed acceptable 
and 0·8–0·9 good.15 We assessed calibration graphically 
with calibration plots, and by computing the ratio of 
expected to recorded probabilities and the accompanying 
95% CIs by assuming a Poisson variance.16 We also 
calculated the Yates slope (diﬀ erence between mean 
predicted probability of type 2 diabetes for participants 
with and without incident diabetes, with higher values 
indicating better performance), and Brier score (squared 
diﬀ erence between predicted probability and actual 
outcome for each participant; these values vary from 0 
for a perfect prediction model to 0·25 for a non-
informative model with 50% incident outcome).17 We 
did not use tests of calibration such as the Hosmer-
Lemeshow test or U statistic,18 because they are sensitive 
to study sample size.
Because we were comparing the performance of 
several models in a case-cohort design across many 
countries, we took some extra steps before model 
validation. First, the models have diﬀ erent so-called 
time horizons. In the main analysis, we compared all 
models for prediction of type 2 diabetes within 10 years. 
Therefore, participants who developed diabetes after 
10 years of follow-up were included as non-cases. 
Second, calibration is strongly aﬀ ected by the outcome’s 
incidence in the population; we therefore recalibrated 
models to the country-speciﬁ c incidence through 
intercept adjustment (appendix pp 9, 12).18,19 These 
approaches eliminate diﬀ erences between the models 
due to diﬀ erences in incidence between the populations 
for which the scores were developed.19 Third, the 
incidence of diabetes is artiﬁ cially increased in the case-
cohort design. To arrive at the true incidences from the 
original cohort, we reconstituted the EPIC cohort within 
countries by applying a so-called blow-up approach to 
extrapolate the case-cohort data to a full cohort (appendix 
p 10).8 Finally, to account for any heterogeneity between 
countries, we estimated the C statistic and ratio of 
expected to recorded probabilities for the entire cohort 
by pooling country-level estimates with random eﬀ ects 
models. We then used the Cochran’s Q and I² statistics 
to assess heterogeneity across countries.
We did the main analyses for each country and for 
subgroups deﬁ ned by sex, age (<60 years vs ≥60 years), 
BMI (<25 kg/m² vs ≥25 kg/m²), and waist circumference 
(men <102 cm vs ≥102 cm; women <88 cm vs ≥88 cm). In 
four of the eight countries (Denmark, Italy, Spain, and 
Sweden), not all models had been validated (appendix 
p 11). We did a sensitivity analysis by restricting the 
assessment of the heterogeneity between countries to the 
four countries in which all models had been validated 
(France, Germany, the Netherlands, and the UK) to 
investigate if assessments of heterogeneity of diﬀ erent 
models on the basis of a diﬀ erent number of countries 
aﬀ ected the comparisons. We also compared all models 
for prediction of diabetes within 5 years, which 
corresponds to the time horizon for predicted probability 
for six models.
We used the Hmisc, Design, Survival, and meta 
packages of R (version 2.13.0) for data analysis.
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Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. APK and JWJB had full access to all 
the data in the study; JWJB, YTvdS, and NJW had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We validated 12 prediction models (table 1, appendix p 7). 
Age was a predictor of type 2 diabetes in all models except 
DESIR.24 Most models were based on logistic regressions 
(table 1). Varying deﬁ nitions for incident diabetes were 
applied (table 1). Data for baseline age and sex were 
available for all participants, but data were missing for 
some participants for some predictors (table 1).
More than half the overall EPIC-InterAct study popu-
lation were women, but the proportion varied by country 
(table 2). French participants were all women, whereas the 
proportion of women among participants in other countries 
ranged from 44% to 81%. Mean baseline age was 54·1 years 
(SD 8·4) in men and 53·5 years (9·0) in women.
During the ﬁ rst 10 years of follow-up, almost 
10 000 cases of incident diabetes were recorded in the 
EPIC-InterAct population (table 2). Discrimination of the 
12 prediction models was acceptable to good, with 
C statistics ranging from 0·76 to 0·81 (ﬁ gure 1, table 3). 
For nine models, the recalibrated calibration curves 
mostly followed the ideal calibration line (ﬁ gure 2; see 
appendix p 21 for calibration curves before recalibration). 
For the ARIC 2009 model,21 the curves were mostly 
steeper than the ideal calibration line, with increasing 
risk (ﬁ gure 2), indicating risk underestimation in high-
risk participants. For the Cambridge23 and DPoRT25 
models, calibration curves were fairly ﬂ at, with increasing 
risk (ﬁ gure 2), indicating risk overestimation in high-risk 
participants. Four models accurately estimated the 
overall rate of incident diabetes, six marginally 
overestimated or underestimated, and two largely 
overestimated (ﬁ gure 2, table 3).
We noted signiﬁ cant heterogeneity in discrimination 
across countries for all models except for the ARIC 2009 
model (ﬁ gure 1). The highest C statistics were almost 
always recorded in France, and the lowest mostly in 
Denmark (ﬁ gure 1). The worst and best discriminating 
models varied by country (ﬁ gure 1). Patterns of calibration 
were largely similar in each country to those recorded for 
the overall cohort (appendix pp 22–33). As expected, 
because of recalibration by country, we recorded almost 
no heterogeneity in calibration.
Discrimination was generally higher in women than 
men (table 3). C statistics in men ranged from 0·73 to 
0·79 in the overall cohort (table 3), and from 0·68 to 
0·86 across countries (appendix p 13). In men, the best 
discrimination was recorded in the Netherlands 
(appendix p 13). In women, C statistics ranged from 
0·78 to 0·81 in the overall cohort (table 3), and from 
0·70 to 0·85 across countries (appendix p 13). The 
highest C statistics in women were mostly recorded in 
Germany, and the lowest in Denmark (appendix p 13). 
Calibration diﬀ ered greatly between men and women 
per country, which could be masked by the overall ratio 
of expected to recorded probabilities (appendix p 13).
Discrimination was acceptable to good across age 
strata, and was always better in the younger age group 
Incident diabetes risk models Variable 
or proxy 
in 
InterAct
Participants 
with missing 
data for 
InterAct
ARIC 
200520
ARIC 
200921
AUS-
DRISK22
Cam-
bridge23
DESIR24 DPoRT25 FINDRISK 
concise6
FINDRISK 
full6
Framingham 
personal26
KORA 
S4/F427
EPIC-
Potsdam28
QD Score29
Year 2005 2009 2010 2008 2008 2010 2003 2003 2007 2010 2007 2009 ·· ··
Cohort size 7915 12 729 6060 24 495 3817 19 861 4595 4435 3140 873 25 167 2 540 753 ·· ··
Follow-up (years) 9 10 5 4·6 9 9 5 5 7 5 5 10 ·· ··
Deﬁ nition of 
incident diabetes
Any 
incident
Any 
incident
Treated 
with 
drugs, 
diag-
nosed 
with 
OGTT
Self-report, 
registries
Treated 
with drugs, 
diag nosed 
with fasting 
glucose 
measure-
ments
Any 
incident
Treated 
with 
drugs
Treated 
with 
drugs
Treated 
with drugs, 
diagnosed 
with fasting 
glucose 
measure-
ments
Diag-
nosed 
with 
OGTT
Diag-
nosed 
with 
OGTT
Any 
incident
·· ··
Number of cases 
of incident 
diabetes
1292 2407 362 323 203 1410 194 182 160 91 849 78 081 ·· ··
Country USA USA Australia UK France Canada Finland Finland USA Germany Germany UK ·· ··
Age group 
included (years)
≥25 45–64 ≥25 40–79 30–64 >20 35–64 35–64 54* 55–74 35–65 25–79 20–79 ··
Statistical model Logistic Weibull Logistic Logistic Logistic Weibull Logistic Logistic Logistic Logistic Cox Cox NA NA
Validation External External External External External External External External External External External External NA NA
(Continues on next page)
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than in the older (table 3). Discrimination was below the 
acceptable range (C statistic <0·70) in the lower stratum 
of waist circumference but was acceptable in the upper 
one. Discrimination was similar across BMI groups, 
although C statistics were higher in people with increased 
BMI than in those with lower BMIs in seven of the 
12 models (table 3).
In terms of calibration, the ARIC 2005,20 AUSDRISK,22 
FINDRISK concise,6 and FINDRISK full models6 
acceptably predicted the overall rate of incident diabetes 
in age subgroups (table 3). The Cambridge model23 
overestimated risk in all participants (table 3). Most other 
models overestimated risk in younger participants and 
underestimated risk in the older people, but we recorded 
Incident diabetes risk models Variable 
or proxy 
in 
InterAct
Participants 
with missing 
data for 
InterAct
ARIC 
200520
ARIC 
200921
AUS-
DRISK22
Cam-
bridge23
DESIR24 DPoRT25 FINDRISK 
concise6
FINDRISK 
full6
Framingham 
personal26
KORA 
S4/F427
EPIC-
Potsdam28
QD Score29
(Continued from previous page)
Predictors
Age Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes 0
Sex No No Yes Yes Sex speciﬁ c† Sex speciﬁ c† No No Yes Yes No Sex speciﬁ c† Yes 0
Smoking No Yes Yes Yes Yes Yes No No No Yes Yes Yes Yes 339
Family history No No No Yes Yes No No No No No No Yes Yes 13 795‡
Parental 
diabetes
Yes Yes Yes No Sex speciﬁ c† No No No Yes Yes No No Yes 15 761‡
Maternal 
diabetes
No Yes No No No No No No No No No No Yes 15 761‡
Hypertension No Yes No Yes Yes Yes No No No Yes Yes Yes Yes 556
Pulse No Yes No No No No No No No No No No Yes 16 311§
Ethnic origin Yes Yes Yes No No Yes No No No No No Yes Yes 0
BMI No No No Yes No Yes Yes Yes Yes Yes No Yes Yes 197
Body weight No Yes No No No No No No No No No No Yes 177
Waist 
circumference
Yes Yes Yes No Yes No Yes Yes No No Yes No Yes 2018
Height Yes Yes No No No No No No No No Yes No Yes 113
Steroid use No No No Yes No No No No No No No Yes NA All¶
High glucose 
concentration
No No Yes No No No Yes Yes No No No No NA All¶
Physical 
activity
No No Yes No No No No Yes No No Yes No Yes 2217
Townsend 
score||
No No No No No No No No No No No Yes NA All¶
Education No Yes No No No Yes No No No No No No Yes 330
Consumption 
of red meat
No No No No No No No No No No Yes No Yes 736
Consumption 
of whole-grain 
bread
No No No No No No No No No No Yes No Yes 736
Coﬀ ee intake No No No No No No No No No No Yes No Yes 736
Alcohol intake No No No No No No No No No No Yes No Yes 117
Immigration 
into country 
where study 
done
No No Yes No No No No No No No No No NA All¶
Systolic blood 
pressure
Yes No No No No No No No No No No No Yes 6343
Heart disease No No No No No Yes No No No No No No Yes 55
 ARIC=Atherosclerosis Risk in Communities. AUSDRISK=Australian Type 2 Diabetes Risk Assessment Tool. DESIR=Epidemiological Study on the Insulin Resistance Syndrome. DPoRT=Diabetes Population Risk Tool. 
FINDRISK=Finnish Diabetes Risk Score. KORA S4/F4=Cooperative Health Research in the Region of Augsburg (KORA), Survey 4. EPIC=European Investigation into Cancer and Nutrition. OGTT=oral glucose tolerance 
test. NA=not applicable. *Mean. †Model built separately for women and men. ‡Predictor completely missing in centres in Italy and Spain. §Predictor completely missing in centres in Denmark and Sweden. ¶All 
27 779 participants. ||Index of social and economic deprivation of a location.
Table 1: Models of incident diabetes risk prediction included
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the opposite ﬁ nding for KORA27 and Potsdam28 models. 
Absolute risk of diabetes was variably overestimated or 
underestimated by models across weight circumference 
strata, while all models systematically overestimated the 
risk within the lower BMI stratum (table 3).
The pattern of overall event rate prediction in the four 
countries with valid data for all models (France, Germany, 
the Netherlands, and the UK) was very similar to that 
across all countries (data not shown), again with 
signiﬁ cant heterogeneity for the Cambridge23 and 
DPoRT25 models (both p≤0·0002). Heterogeneity in 
discrimination across countries decreased when we 
examined data for countries with full data, with the ARIC 
2009,21 DPoRT,25 and FINDRISK6 models showing no 
heterogeneity (p>0·11).
During the ﬁ rst 5 years of follow-up, 3698 cases of 
incident diabetes were recorded (table 2). Discrimination 
was slightly better and less heterogeneous at 5 years than 
at 10 years; otherwise, the pattern of predictions was 
broadly similar to that recorded at 10 years 
(appendix pp 16–20, 34–36).
Discussion
We have shown that non-invasive models for prediction 
of incident type 2 diabetes have acceptable to good 
discrimination over 10 years, both overall and across 
countries. After recalibration, most models showed good 
calibration, which was consistent across countries, 
although discrimination varied signiﬁ cantly. We showed 
that the models’ performance is worse in men than in 
women. Discrimination is better in people younger than 
60 years, but risk can be overestimated in this age group. 
Discrimination is generally lower in participants with a 
BMI of less than 25 kg/m² than in those with a BMI of at 
least 25 kg/m². Risk is systematically overestimated in 
participants with a BMI of less than 25 kg/m². No model 
signiﬁ cantly outperforms others enough to be uniquely 
recommended for routine risk stratiﬁ cation.
A few previous validation studies of incident diabetes 
models have been done.4,5,8,21,24,30–34 Most of those—mainly 
cross-sectional studies—compared several incident or 
prevalent risk scores in one population,21,24,32–34 and 
another study compared three risk scores in a multiethnic 
population in the same country.30 In one study,8 the 
performance of both invasive and non-invasive prediction 
models for incident diabetes in a population was 
assessed. Overall, the previous studies showed that the 
models had modest to good discrimination and poor 
calibration. However, intercept adjustment to correct for 
diﬀ erences in diabetes incidence between development 
and validation populations was done in only one study.
Models’ performance (mostly discrimination) diﬀ ered 
across countries in our study. This variation could be a 
result of diﬀ erences in how predictors and outcomes 
Overall Denmark France Germany Italy Netherlands Spain Sweden UK
Participating centres 26 2 6 2 5 2 5 2 2
Total eligible EPIC cohort 326 805 20 410 45 877 36 755 35 471 35 093 46 104 52 146 54 949
Total InterAct case-cohort 27 779 4037 867 3578 3393 2290 5889 5401 2324
Women 15 887 (57·2%) 1787 (44·3%) 867 (100%) 1795 (50·2%) 2177 (64·2%) 1845 (80·6%) 3323 (56·4%) 2824 (52·3%) 1269 (54·6%)
Age (years) 53·7 (8·7) 57·0 (4·4) 56·9 (6·5) 52·4 (8·3) 51·3 (7·7) 53·7 (10·2) 50·3 (7·8) 54·9 (9·7) 58·5 (10·2)
Smoking
Never 12 335 (44·4%) 1264 (31·3%) 588 (67·8%) 1529 (42·7%) 1509 (44·5%) 908 (39·7%) 3149 (53·5%) 2309 (42·8%) 1079 (46·4%)
Former 8026 (28·9%) 1281 (31·7%) 200 (23·1%) 1286 (35·9%) 925 (27·3%) 762 (33·3%) 1028 (17·5%) 1618 (30·0%) 926 (39·8%)
Current 7418 (26·7%) 1492 (37·0%) 79 (9·1%) 763 (21·3%) 959 (28·3%) 620 (27·1%) 1712 (29·1%) 1474 (27·3%) 319 (13·7%)
Hypertension* 7461 (26·9%) 1020 (25·3%) 172 (19·8%) 1506 (42·1%) 912 (26·9%) 626 (27·3%) 1469 (24·9%) 1332 (24·7%) 424 (18·2%)
Systolic blood pressure 
(mm Hg)
136 (21) 144 (21) 130 (20) 134 (19) 134 (19) 133 (22) 132 (20) 140 (20) 139 (20)
Pulse rate (beats per min) 73 (12) NA 70 (11) 74 (12) 71 (9) 74 (12) 74 (12) NA 71 (12)
BMI (kg/m²) 27·6 (4·8) 27·4 (4·6) 24·6 (4·8) 27·7 (4·9) 27·5 (4·9) 26·6 (4·5) 29·4 (4·6) 26·8 (4·6) 27·1 (4·7)
Waist circumference (cm) 91 (14) 93 (14) 80 (12) 92 (14) 88 (13) 87 (13) 95 (12) 89 (14) 89 (14)
Hip circumference (cm) 103 (9) 103 (9) 101 (10) 103 (9) 102 (9) 104 (9) 107 (9) 101 (10) 103 (9)
Family history of diabetes 4907 (26·5%)† 955 (23·7%) 147 (17·0%) 1114 (31·1%) NA 771 (33·7%) NA 1534 (28·4%) 386 (16·6%)
Follow-up (days) 3968 
(2603–4634)
3745 
(2299–4242)
3391 
(2603–3835)
3472 
(1766–4099)
3967 
(2480–4638)
4065 
(2389–4655)
4557 
(3262–4975)
4334 
(3335–4952)
3797 
(2294–4401)
Cases of incident diabetes during follow-up
Overall 12 403 2055 288 1584 1437 828 2564 2622 1025
Within 5 years 3698 633 132 916 470 406 418 418 305
Within 10 years 9951 1845 278 1554 1292 778 1759 1520 925
Data are n, n (%), mean (SD), or median (IQR). Includes imputed data for those with missing values. NA=not available. *Self-reported diagnosis or use of drugs, or both. †Percentage calculated with number of 
individuals for whom data available (ie, not Italy and Spain; n=18 497).
Table 2: Baseline characteristics of the InterAct case-cohort and cases of incident diabetes during follow-up, overall and by country 
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C statistic (95% CI)
ARIC 2005
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98·6%, τ2=0·0021, p<0·0001
0·73 (0·72–0·73)
0·84 (0·81–0·86)
0·81 (0·80–0·82)
0·83 (0·82–0·84)
0·77 (0·76–0·78)
0·79 (0·78–0·81)
0·79 (0·76–0·83)
0·81 (0·79–0·84)
0·80 (0·79–0·81)
0·81 (0·80–0·83)
0·79 (0·78–0·81)
0·80 (0·79–0·81)
ARIC 2009
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=18·5%, τ2<0·0001, p=0·298
0·71 (0·70–0·72)
0·80 (0·77–0·83)
0·79 (0·78–0.·80)
0·81 (0·80–0·82)
0·74 (0·72–0·75)
0·76 (0·74–0·77)
0·77 (0·73–0·80)
AUSDRISK
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98%, τ2=0·002, p<0·0001
0·72 (0·71–0·73)
0·82 (0·80–0·84)
0·81 (0·80–0·82)
0·81 (0·80–0·82)
0·78 (0·77–0·79)
0·78 (0·77–0·80)
0·79 (0·75–0·82)
Cambridge
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98·2%, τ2=0·0019, p<0·0001
0·72 (0·72–0·73)
0·85 (0·83–0·87)
0·81 (0·80–0·82)
0·82 (0·81–0·83)
0·76 (0·75–0·78)
0·80 (0·79–0·81)
0·79 (0·76–0·83)
DESIR
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98·5%, τ2=0·0021, p<0·0001
0·71 (0·69–0·71)
0·81 (0·78–0·84)
0·79 (0·78–0·80)
0·76 (0·75–0·77)
0·79 (0·78–0·81)
0·73 (0·72–0·74)
0·76 (0·75–0·77)
0·77 (0·76–0·79)
0·76 (0·74–0·79)
DPoRT
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=97·4%, τ2=0·0014, p<0·0001
0·70 0·850·800·75 0·90
C statistic 
C statistic (95% CI)
FINDRISK concise
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=97·8%, τ2=0·0014, p<0·0001
0·72 (0·71–0·73)
0·80 (0·78–0·83)
0·81 (0·80–0·82)
0·78 (0·76–0·79)
0·81 (0·79–0·82)
0·74 (0·73–0·75)
0·76 (0·75–0·77)
0·79 (0·78–0·80)
0·78 (0·75–0·80)
0·72 (0·71–0·73)
0·80 (0·78–0·83)
0·80 (0·80–0·81)
0·77 (0·76–0·78)
0·80 (0·79–0·82)
0·74 (0·73–0·75)
0·76 (0·75–0·77)
0·79 (0·77–0·80)
0·77 (0·75–0·80)
FINDRISK full
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=97·4%, τ2=0·0013, p<0·0001   
0·69 (0·68–0·70)
0·82 (0·80–0·85)
0·78 (0·77–0·79)
0·80 (0·79–0·82)
0·74 (0·73–0·76)
0·76 (0·74–0·77)
0·76 (0·72–0·80)
Framingham personal
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98·5%, τ2=0·0024, p<0·0001
0·72 (0·71–0·72)
0·82 (0·80–0·84)
0.80 (0.79–0.81)
0·82 (0·81–0·83)
0·76 (0·75–0·77)
0·77 (0·76–0·79)
0·78 (0·74–0·82)
KORA S4/F4
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98·3%, τ2=0·0021, p<0·0001
0·72 (0·72–0·73)
0·84 (0·81–0·86)
0.82 (0.81–0.83)
0·78 (0·77–0·80)
0·83 (0·81–0·84)
0·76 (0·75–0·77)
0·77 (0·76–0·78)
0·80 (0·78–0·81)
0·79 (0·76–0·82)
Potsdam
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98%, τ2 =0·0015, p<0·0001
0·73 (0·73–0·74)
0·85 (0·82–0·87)
0·82 (0·81–0·83)
0·84 (0·83–0·85)
0·80 (0·79–0·81)
0·81 (0·79–0·82)
0·81 (0·77–0·84)
QDscore
Denmark
France
Germany
Italy
Netherlands
Spain
Sweden
UK
Overall
Tests for heterogeneity: I2=98·6%, τ2=0·0021, p<0·0001
0·70 0·850·800·75 0·90
C statistic 
Figure 1: Discrimination of the diﬀ erent models for the prediction of incident type 2 diabetes at 10 years of follow-up overall and by country
Discrimination refers to the ability of the model to distinguish between participants who did and did not develop diabetes during 10 years of follow-up. ARIC=Atherosclerosis Risk in Communities. 
AUSDRISK=Australian Type 2 Diabetes Risk Assessment Tool. DESIR=Epidemiological Study on the Insulin Resistance Syndrome. DPoRT=Diabetes Population Risk Tool. FINDRISK=Finnish Diabetes Risk 
Score. KORA S4/F4=Cooperative Health Research in the Region of Augsburg (KORA), Survey 4.
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were measured (for discrimination) and in baseline 
diabetes risk (for calibration) across countries. The 
FINDRISK concise model6 was previously tested in ﬁ ve 
cohorts from Europe, North America, and Australia.35 
Discrimination varied by country, with C statistics 
between 0·63 and 0·78,35 which is consistent with our 
Overall Men Women Age
<60 years
Age
≥60 years
BMI
<25 kg/m2
BMI
≥25 kg/m2
Waist circumference 
≥102 cm in men or 
≥88 cm in women
Waist circumference 
<102 cm in men or 
<88 cm in women
C statistics
ARIC 2005 0·79 
(0·76–0·83)*
0·75 
(0·73–0·78)*
0·81 
(0·77–0·84)*
0·81 
(0·77–0·85)*
0·73 
(0·69–0·76)*
0·73 
(0·66–0·80)*
0·71 
(0·69–0·73)*
0·66
(0·65–0·67)†
0·75
(0·70–0·79)*
ARIC 2009 0·80 
(0·79–0·81)
0·79 
(0·74–0·83)*
0·81 
(0·80–0·82)
0·82 
(0·81–0·83)
0·74 
(0·71–0·77)‡
0·71 
(0·68–0·73)
0·73 
(0·71–0·74)
0·66
(0·63–0·69)‡
0·75
(0·73–0·76)
AUSDRISK 0·77 
(0·73–0·80)*
0·73 
(0·70–0·76)*
0·78 
(0·74–0·82)*
0·78 
(0·74–0·82)*
0·70 
(0·68–0·72)‡
0·69 
(0·64–0·74)*
0·71 
(0·68–0·73)*
0·64
(0·63–0·66)†
0·69
(0·65–0·73)*
Cambridge model 0·79 
(0·75–0·82)*
0·76 
(0·73–0·79)*
0·80 
(0·76–0·83)*
0·80 
(0·76–0·84)*
0·72 
(0·70–0·74)*
0·70 
(0·65–0·75)*
0·70 
(0·68–0·72)*
0·66
(0·64–0·68)*
0·74
(0·69–0·79)*
DESIR model 0·79 
(0·76–0·83)*
0·73 
(0·71–0·75)*
0·81 
(0·77–0·85)*
0·81 
(0·77–0·85)*
0·74 
(0·71–0·77)*
0·71 
(0·65–0·76)*
0·72 
(0·69–0·74)*
0·65
(0·63–0·67)*
0·71
(0·67–0·76)*
DPoRT model 0·76 
(0·74–0·79)*
0·73 
(0·71–0·75)*
0·78 
(0·75–0·81)*
0·78 
(0·75–0·81)*
0·70 
(0·68–0·73)*
0·63 
(0·59–0·67)*
0·68 
(0·66–0·69)*
0·64
(0·63–0·65)‡
0·72
(0·68–0·75) *
FINDRISK concise 0·78 
(0·75–0·80)*
0·75 
(0·72–0·78)*
0·79 
(0·76–0·81)*
0·79 
(0·76–0·82) *
0·71 
(0·69–0·73)*
0·68 
(0·64–0·71)*
0·70 
(0·69–0·72)*
0·63
(0·62–0·65)*
0·72
(0·68–0·75)*
FINDRISK full model 0·77 
(0·75–0·80)*
0·74 
(0·72–0·77)*
0·78 
(0·76–0·81)*
0·78 
(0·75–0·81)*
0·71 
(0·68–0·73)*
0·68 
(0·65–0·72)*
0·70 
(0·69–0·72)*
0·63
(0·62–0·65)§
0·71
(0·67–0·74)*
Framingham personal 0·76 
(0·72–0·80)*
0·74 
(0·70–0·77)*
0·78 
(0·74–0·82)*
0·78 
(0·74–0·83)*
0·69 
(0·67–0·73)*
0·64 
(0·57–0·70)*
0·65 
(0·63–0·60)*
0·61
(0·60–0·63)†
0·70
(0·65–0·75)*
KORA model 0·78 
(0·74–0·82)*
0·75 
(0·71–0·79)*
0·79 
(0·75–0·82)*
0·80 
(0·76–0·84)*
0·72 
(0·69–0·74)*
0·73 
(0·67–0·78)*
0·70 
(0·68–0·73)*
0·66
(0·65–)·68)‡
0·75
(0·70–0·79)*
Potsdam model 0·79 
(0·76–0·82)*
0·74 
(0·72–0·77)*
0·81 
(0·78–0·83)*
0·80 
(0·77–0·83)*
0·72 
(0·70–0·75)*
0·74 
(0·68–0·79)*
0·72 
(0·70–0·73)*
0·66
(0·65–0·68)§
0·75
(0·71–0·78)*
QDScore 0·81 
(0·77–0·84)*
0·78 
(0·74–0·82)*
0·81 
(0·77–0·85)*
0·82 
(0·78–0·86)*
0·75 
(0·72–0·77)*
0·75 
(0·69–0·80)*
0·72 
(0·70–0·75)*
0·68
(0·66–0·70)*
0·77
(0·72–0·82)*
Ratios of expected to observed rates
ARIC 2005 1·06 
(1·04–1·08)
1·08 
(1·02–1·14)‡
1·06 
(0·97–1·15)*
1·02 
(0·98–1·06)†
1·11 
(1·03–1·19)§
2·22 
(1·74–2·68)*
0·83 
(0·74–0·93)*
0·74
(0·65–0·82)*
1·49
(1·34–1·64)*
ARIC 2009 1·04 
(1·01–1·08)
1·01 
(0·84–1·17)*
1·13 
(0·96–1·30)*
1·20 
(1·14–1·27)
0·79 
(0·69–0·88)‡
2·90 
(2·60–3·21)
0·69 
(0·56–0·81)*
0·55
(0·56–0·65)*
1·72
(1·56–1·88)*
AUSDRISK 1·00 
(0·98–1·02)
1·11 
(1·02–1·18)§
0·93 
(0·86–1·00)*
1·03 
(0·99–1·08)
0·97 
(0·87–1·02)§
2·29 
(1·70–2·81)*
0·75 
(0·67–0·83)*
0·77
(0·68–0·86)*
1·31
(1·17–1·45)*
Cambridge model 1·40 
(1·28–1·52)*
1·76 
(1·59–1·94)*
1·14 
(0·98–1·30)*
1·29 
(1·17–1·42)*
1·53 
(1·30–1·77)*
1·27 
(0·99–1·55)*
1·42 
(1·30–1·53)*
1·30
(1·20–1·41)*
1·54
(1·34–1·73)*
DESIR model 1·06 
(1·02–1·11)‡
1·06 
(1·03–1·08)
1·06 
(0·99–1·13)§
1·18 
(1·12–1·24)‡
0·88 
(0·83–0·92)
1·35 
(1·07–1·64)*
1·02 
(0·98–1·06)†
1·13
(1·05–1·22)*
0·99
(0·89–1·10)*
DPoRT model 1·34 
(1·29–1·39)‡
1·58 
(1·51–1·64)†
1·14 
(1·11–1·17)
1·44 
(1·39–1·49)†
1·07 
(0·95–1·18)*
1·58 
(1·33–1·83)*
1·30 
(1·23–1·36)*
1·00
(0·92–1·07)*
1·80
(1·67–1·93)*
FINDRISK concise 0·98 
(0·96–0·99)
0·85 
(0·79–0·91)*
1·11 
(1·02–1·19)*
1·00 
(0·97–1·03)
0·94 
(0·88–1·01)§
1·28 
(1·04–1·51)*
0·93 
(0·90–0·97)§
1·08
(1·03–1·13)*
0·84
(0·79–0·90)*
FINDRISK full model 0·98 
(0·96–0·99)
0·89 
(0·84–0·95)*
1·07 
(1·00–1·15)*
1·00 
(0·97–1·03)
0·94 
(0·88–1·00)§
1·37 
(1·12–1·62)*
0·92 
(0·88–0·96)*
1·06
(1·01–1·11)*
0·88
(0·82–0·93)*
Framingham personal 0·99 
(0·98–1·02
0·78 
(0·70–0·87)*
1·22 
(1·09–1·35)*
1·12 
(1·07–1·16)
0·81 
(0·76–0·86)†
1·67 
(1·30–2·05)*
0·88 
(0·82–0·94)*
0·73
(0·66–0·79)*
1·36
(1·23–1·50)*
KORA model 1·00 
(0·97–1·02)
1·09 
(1·06–1·12)
0·91 
(0·84–0·99)*
0·82 
(0·74–0·91)*
1·26 
(1·15–1·37)*
1·70 
(1·37–2·02)*
0·87 
(0·82–0·92)§
0·77
(0·73–0·80)†
1·31
(1·21–1·42)*
Potsdam model 0·98 
(0·97–1·00)
1·06 
(1·01–1·11)†
0·93 
(0·85–1·02)*
0·90 
(0·85–0·94)†
1·17 
(1·08–1·25)*
1·38 
(1·12–1·64)*
0·93 
(0·88–0·97)*
0·96
(0·90–1·03)*
1·04
(0·94–1·14)*
QDScore 1·06 
(1·04–1·08)
1·08 
(1·05–1·11)*
1·04 
(1·01–1·07)
1·04 
(0·99–1·10)‡
1·22 
(1·07–1·36)*
1·40 
(1·15–1·65)*
0·99 
(0·93–1·05)*
0·87
(0·80–0·94)*
1·29
(1·19–1·39)*
 ARIC=Atherosclerosis Risk in Communities. AUSDRISK=Australian Type 2 Diabetes Risk Assessment Tool. DESIR=Epidemiological Study on the Insulin Resistance Syndrome. DPoRT=Diabetes Population Risk Tool. 
FINDRISK=Finnish Diabetes Risk Score. KORA S4/F4=Cooperative Health Research in the Region of Augsburg (KORA), Survey 4. *pheterogeneity<0·0001. †pheterogeneity<0·05. ‡pheterogeneity<0·01. §pheterogeneity<0·001.
Table 3: Discrimination and calibration of models for the prediction of incident type 2 diabetes at 10 years of follow-up overall and by subgroup
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Ideal
Non-parametric
Grouped observations
Yates slope 0·052
Brier score 0·034
0·05 0·10 0·15 0·20 0
Predicted probability
0·05 0·10 0·15 0·20 0
Predicted probability
0·05 0·10 0·15 0·20
Yates slope 0·026
Brier score 0·024
Yates slope 0·054
Brier score 0·034
Yates slope 0·11
Brier score 0·037
Yates slope 0·080
Brier score 0·036
Yates slope 0·068
Brier score 0·035
Yates slope 0·063
Brier score 0·034
Yates slope 0·063
Brier score 0·035
Yates slope 0·046
Brier score 0·035
Yates slope 0·067
Brier score 0·035
Yates slope 0·073
Brier score 0·035
Yates slope 0·077
Brier score 0·034
ARIC 2005 ARIC 2009 AUSDRISK 
Cambridge DESIR DPoRT
FINDRISK concise
KORA S4/F4 Potsdam QDScore
FINDRISK full Framingham personal
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results. Therefore, risk scores might not always be 
generalisable to populations other than the development 
population.
We noted some consistent trends across countries. 
Discrimination was generally low for the DPoRT model,25 
potentially because this model was developed to estimate 
diabetes risk in a population rather than for an individual, 
which could aﬀ ect quality of the predictors and outcome 
data. The QDScore29 was one of the best discriminatory 
models across countries. It is based on more predictors 
than other models are and so uses more information, 
and was developed from a large sample, providing 
precise estimates of the associations between predictors 
and outcomes. Calibration of the Cambridge model23 was 
generally poor. Although validated for incident diabetes 
prediction,36 this model was developed as a diagnostic 
model, which could have inﬂ ated estimates of the 
association between diabetes and predictors.
We recorded substantial variation in models’ 
performance by major subgroups, with consistently 
better performance in women than in men. For the 
DESIR24 and DPoRT25 models and the QDScore,29 this 
diﬀ erence could be a result of the use of sex-speciﬁ c 
coeﬃ  cients that could eﬃ  ciently capture the predictive 
information from risk factors. BMI and waist 
circumference are generally much stronger diabetes 
predictors in women than in men and could also explain 
these results.37,38 In our study, the diﬀ erences in 
discrimination linked to BMI were small. BMI and waist 
circumference might not be linearly related to diabetes 
risk.37 By including linear or categorical terms of these 
predictors, most models might not completely capture 
the nature of the associations. Our ﬁ nding that 
discrimination is mostly better in younger than in older 
participants is consistent with a previous validation of 
the KORA model.39 However, stratiﬁ cation for a variable 
with discriminatory value by itself reduces discrimination.
The European guideline for the prevention of type 2 
diabetes10 and the International Diabetes Federation9 
recommend the use of reliable, straightforward, and 
practical prediction models to identify people at high risk 
of diabetes. Overall, our study shows that prediction 
models for type 2 diabetes are valid instruments for the 
identiﬁ cation of individuals at high risk. However, this 
ﬁ nding cannot directly be translated into a 
recommendation to use a speciﬁ c model, because the 
decision to adopt a prediction model in any speciﬁ c 
setting is driven by many factors, of which performance 
is only one.
For individuals, highly accurate risk scores including 
biochemical testing are probably more relevant than 
non-invasive risk models are.8 However, non-invasive 
risk scores could be used as part of the public health 
approach to diabetes prevention to identify individuals 
who should receive biochemical testing. Alternatively, a 
risk score could be used to identify a subgroup of the 
population for lifestyle intervention without additional 
testing. Mortality risk is increased in the large group of 
people who have positive risk scores, justifying direct 
action in this group.40 Risk scores like those in the 
Cambridge model23 and QDScore29 in the UK, or the 
DPoRT model in Canada,25 use data available from 
records in the countries where models were developed, 
and new data are not needed. Because such scores are 
likely to be applicable to anyone coming into contact with 
the health system, their performance could be better 
overall than that of another model with a slightly better 
discrimination. Nevertheless, a model for which a 
questionnaire is designed for self-screening at the 
population level (eg, the two FINDRISK models) might 
not be based on many responses, potentially overriding 
any performance advantage recorded in our analysis.41
Therefore, the decision to use a particular model 
could be country speciﬁ c and depends on factors other 
than model performance, such as availability of 
measurements in the setting where the model is used. 
Additionally, prediction of diabetes is useful only when 
used to implement interventions to aﬀ ect the outcomes 
of high-risk people.4 Diabetes prevention trials have 
been mostly based on a high-risk status deﬁ ned by 
blood tests. However, implementation studies are 
necessary to investigate eﬀ ectiveness of such risk 
scores. A few implementation studies have used risk 
scores to select participants for interventions and have 
shown favourable eﬀ ects on risk factor levels42—eg, a 
moderate weight loss eﬀ ectively reduced risk of type 2 
diabetes after 1 year of intervention in participants 
selected with the FINDRISK score.43
Our study has some limitations. Some of the 
approaches used to account for predictors that were 
completely missing (ie, proxy variables, predictor 
omission, and country’s exclusion) could marginally 
decrease discrimination of the models. It is now widely 
accepted that deletion of participants with missing 
values (who are frequent in large studies) yields biased 
results.39 Therefore, we applied robust methods to deal 
with missing data.44 The large sample and the 
multicountry nature of our study has allowed us to 
assess and compare 12 models across countries for the 
ﬁ rst time (panel). However, we did not include non-
European participants. Therefore, our results might not 
be generalisable to non-European countries or other 
Figure 2: Calibration curves for each model for the prediction of incident 
type 2 diabetes at 10 years of follow-up for the total cohort
Calibration of a model describes the extent to which the expected probability of 
diabetes matches the recorded probability of diabetes during follow-up. The ideal 
calibration (perfect agreement) is graphically represented by the dotted diagonal 
line at 45°. The vertical lines at the bottom of the graph depict the frequency 
distribution of the calibrated probabilities of diabetes. Grouped observations are 
for groups of participants across increasing deciles of predicted risk. 
ARIC=Atherosclerosis Risk in Communities. AUSDRISK=Australian Type 2 Diabetes 
Risk Assessment Tool. DESIR=Epidemiological Study on the Insulin Resistance 
Syndrome. DPoRT=Diabetes Population Risk Tool. FINDRISK=Finnish Diabetes Risk 
Score. KORA S4/F4=Cooperative Health Research in the Region of Augsburg 
(KORA), Survey 4.
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ethnic groups. Finally, case deﬁ nition was based on a 
clinical diagnosis of diabetes. Because diabetes can 
remain undetected, false-negative cases could have been 
present. Such false negatives could lead to an 
underestimation of the C statistic and aﬀ ect the 
incidence of diabetes, aﬀ ecting calibration of the risk 
scores. However, we adjusted for such eﬀ ects of diabetes 
incidence by recalibrating the models.
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